• mRNA-1273 is a vaccine candidate developed by Moderna and the National Institute of Allergy and Infectious Disease (NIAID) Vaccine Research Center, using prior studies of related coronaviruses, such as severe acute respiratory syndrome and Middle East respiratory syndrome. The clinical trial began recruiting in mid-March and is being conducted at the Kaiser Permanente Washington Health Research Institute in Seattle.

    That is great

    • This reply was modified 1 year, 8 months ago by HerbertB.
  • You must be logged in to reply to this topic.